US 12097199
Administration of SUMO-activating enzyme inhibitor and anti-CD20 antibodies
granted A61KA61K31/505A61K31/506
Quick answer
US patent 12097199 (Administration of SUMO-activating enzyme inhibitor and anti-CD20 antibodies) held by Takeda Pharmaceutical Company Limited expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Takeda Pharmaceutical Company Limited
- Grant date
- Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 21
- CPC classes
- A61K, A61K31/505, A61K31/506, A61K39/395, A61P